Adverum Biotechnologies Files Proxy Supplement
| Field | Detail |
|---|---|
| Company | Adverum Biotechnologies, Inc. |
| Form Type | DEFA14A |
| Filed Date | May 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy, annual-meeting, filing-update
TL;DR
Adverum filed proxy docs for June 17th meeting. No fee. Old name Avalanche.
AI Summary
Adverum Biotechnologies, Inc. filed a Definitive Additional Materials proxy statement on May 23, 2025, supplementing information for their Annual Meeting of Stockholders scheduled for June 17, 2025. The filing relates to the company's proxy materials and does not involve a fee, as indicated by the 'No fee required' checkbox. The company was formerly known as Avalanche Biotechnologies, Inc. until a name change on September 21, 2010.
Why It Matters
This filing provides updated proxy materials for Adverum's upcoming annual meeting, which is crucial for shareholders to understand before voting on company matters.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not contain new financial information or strategic changes that would inherently increase risk.
Key Players & Entities
- Adverum Biotechnologies, Inc. (company) — Registrant
- June 17, 2025 (date) — Annual Meeting Date
- May 23, 2025 (date) — Filing Date
- Avalanche Biotechnologies, Inc. (company) — Former Company Name
- September 21, 2010 (date) — Date of Name Change
FAQ
What type of filing is this?
This is a Definitive Additional Materials proxy statement (DEFA14A).
When is the Annual Meeting of Stockholders scheduled?
The Annual Meeting of Stockholders is scheduled to be held on June 17, 2025.
Was there a fee associated with this filing?
No, the filing indicates 'No fee required'.
What was Adverum Biotechnologies, Inc. formerly known as?
Adverum Biotechnologies, Inc. was formerly known as Avalanche Biotechnologies, Inc.
When did the company change its name?
The company changed its name on September 21, 2010.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 23, 2025 regarding Adverum Biotechnologies, Inc..